size : 26 x 12cm

POST OFFER PUBLIC ANNOUNCEMENT TO THE SHAREHOLDERS OF

KDL BIOTECH LIMITED

(**Registered Office:** Village: Savroli, Taluka: Khalapur, District: Raigad, Maharashtra - 410 202.
Tel. No: 91-2192-274025-274030, Fax No. 91-2192-274031, E-mail: kopran@giasbm01.vsnl.net.in;
Website: www.kdlbiotech.com)

This Post Offer Public Announcement (the "**Post Offer PA**") is being issued by Edelweiss Capital Limited ("**Manager to the Offer**"), on behalf of Unimark Remedies Limited ("**Acquirer**" or "**Unimark**") to the equity shareholders of KDL Biotech Limited ("**KDL**" or "**Target Company**") pursuant to Regulations 10 & 12 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and subsequent amendments thereto (the "SEBI (SAST) Regulations").

The details subsequent to the completion of the Offer which was made vide a) Public Announcement published on July 28, 2008, b) Corrigendum to Public Announcement (collectively "**PAs**") published on September 11, 2008 and c) The Letter of Offer dated September 4, 2008 ("**LOF**") dispatched to the shareholders of KDL ("**Shareholders**") whereby, the Acquirer has made an open offer to the Shareholders to acquire upto 4,807,030 fully paid-up equity shares of the face value of Rs. 10/- each representing 20% of the Expanded Voting Capital of the **Target Company** at a price of Rs. 12/- (Rupees Twelve Only) each per fully paid up equity share ("**Offer Price**"), payable in cash, are as under:

1. Name of the Target Company : KDL Biotech Limited
2. Name of Acquirer(s) including Persons acting in Concert (PACs) : Unimark Remedies Limited (Acquirer)
3. Name of Manager to the Offer : Edelweiss Capital Limited
4. Name of the Registrar to the offer, if any : Bigshare Services Private Limited
5. Offer Details
   a. Date of opening of the offer : Friday, September 19, 2008
   b. Date of closure of the offer : Wednesday, October 08, 2008
6. Details of the acquisition

Sr. No.	Item	Proposed in the Offer Document		Actuals	
1	Offer price	Rs. 12/- per fully paid up equity share		Rs. 12/- per fully paid up equity share	
2	Shareholding of Acquirer (No. & %) before the MOU/PA	2,481,614 (10.33%)(1)		2,481,614 (10.33%)(1)	
3a	Shares allotted pursuant to Share Subscription Agreement through Preferential Issue (No. & %)	7,272,727 (30.26%)		7,272,727 (30.26%)	
3b	Shares acquired by way of Share Purchase Agreements ("**SPAs**") (No. & %)	5,880,025 (24.46%)		Nil(2)	
4	Shares acquired in the open offer (No. & %)	4,807,030 (20.00%)		915,544 (3.81%)	
5	Size of the open offer (No. of shares multiplied by offer price per share)	Rs. 57,684,360		Rs. 10,986,528	
6	Shares acquired after P.A. but before 7 working days prior to closure date, if any .(No. & %) 6.1 Price of the shares acquired 6.2 No of shares acquired 6.3 % of shares acquired	Nil		Nil	
7	Post offer share holding of Acquirer (No. & %) (2+3a+3b+4+6)	20,441,396 (85.05%)		10,669,885 (44.39%)(3)	
8	Pre & Post offer share holding of Public (No & %)	**Pre offer**	**Post offer**	**Pre offer**	**Post offer**
		8,396,195 (34.93%)	3,593,755(4) (14.95%)	8,396,195 (34.93%)	7,485,241(4) (31.14%)

Notes:

All percentages are calculated against fully paid up expanded voting capital of 24,035,151 equity shares including the preferential allotment of 7,272,727 equity shares to Unimark Remedies Limited.

(1) The Acquirer had acquired 1,743,192 Shares at the price of Rs. 9.40/- per share through a Block deal on BSE on 25th July, 2008 and 738,422 shares at a price of Rs. 8.50/- per Share of the Target Company, through an off-market transaction on 25th July, 2008.

(2) As on the date of this Post Offer PA, the transfer of shares under the SPAs is yet to be completed.

(3) Post Offer shareholding of Acquirer after transfer of shares under SPAs will be 16,549,910 (68.86% of the Expanded Voting Capital).

(4) Includes 4,590 equity shares sold by erstwhile Promoters of KDL Biotech Limited to individuals categorized under "Public".

7. Status of Escrow Account, whether released or not: Released
8. Payment of interest, if any, to the Shareholders along with the details thereof: Not Applicable.
9. Status of investor complaints received, if any: No investor complaints are pending as on date.

The Acquirer and Board of Directors of the Acquirer (having a registered office at 19, Crystal, 1st Floor, Juhu Road, Santacruz (West), Mumbai – 400 054.) accept joint and several responsibilities for the information contained in this Post Offer PA and for the fulfillment of their obligations under the SEBI (SAST) Regulations.

This Post Offer PA should be read in conjunction with the PAs and the LOF. Capitalized terms not specifically defined herein shall have the meaning assigned in the PAs and the LOF.

This Post Offer PA is issued, on behalf of the Acquirer, by Edelweiss Capital Limited, Manager to the offer.

This Announcement would also be available on the SEBI website at http://www.sebi.gov.in

For and on behalf of the Acquirer

Edelweiss
Ideas create, values protect

Edelweiss Capital Limited
Express Tower, 14th Floor, Nariman Point, Mumbai – 400 021,
Tel : + 91 22 4086 3535 Fax: + 91 22 4086 3610
Email: kbl.openoffer@edelcap.com
Contact Person: Mr. Viral Shah

Place: Mumbai
Dated: November 18, 2008